spacer
home > pmps > summer 2019 > the long and the short of transdermal drug delivery
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Long and the Short of Transdermal Drug Delivery

For nearly 20 years, my career has been focused on the medical technology industry. While things have changed dramatically during that time in a variety of ways, I’ve discovered that this quote by the European writer Jean-Baptiste Alphonse Karr rings true: “Plus ça change, plus c’est la même chose”/ “The more things change, the more they stay the same”. While technology is changing the landscape in often unpredictable ways, the process for developing a new product and getting it to market remains all too predictable, and this takes a lot of time and a lot of resources.

Experience in this business is a key factor for success. At 3M Drug Delivery Systems (DDS), we have over 60 years in the inhalation business. From the formulation of a new idea during the R&D phase to the manufacturing and packing of the final product, 3M DDS draws upon experience to help support its partners at every point in their journey.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
At 3M, we apply science in collaborative ways to improve lives daily. With $33 billion in sales, our 93,000 employees connect with customers all around the world. Learn more about 3M’s creative solutions to the world’s problems at www.3M.com or on Twitter @3M or @3MNews
spacer
Stephan Brakel
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

Event profile: PHARMAPACK 2020

6-7 February 2020,

Nemera will join more than 5,000 senior pharma professionals at Pharmapack, which will take place in Paris, on 5-6 February 2020. Meet Nemera at the booth C56 to discover its innovative drug delivery devices and its end-to-end development offerings! 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement